ADVERTISEMENT

Evaluate Data

Empty Promises: Five Drugs That Fell Short Of Their Sales Forecasts

Many assets underperform their pre-launch sales predictions, which can be disastrous to their developers and marketers. In this article, Scrip highlights several historic examples and the factors that influenced their poorer-than-expected performance.

Pharma Growth And Biotech Squeeze Will Shape Sector To 2030, Evaluate Forecasts

Evaluate’s five-year forecast sees steady growth for big pharma despite recent political turmoil but tougher times ahead for the ‘have nots’ of biotech.

Defying Gravity: Five Drugs That Surpassed Their Sales Forecasts

Many assets outperform their pre-launch sales predictions despite the frequent overestimation of forecasts within the industry. In this article, Scrip highlights several such assets and the factors that influenced their predictions.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.

Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart

The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.

Lighting The Way To Anxiety Treatments With No Side Effects

Cutting-edge research is revolutionizing anxiety treatment by targeting specific brain circuits, paving the way for therapies that are free from side effects. This innovative approach promises more efficient and precise medicine, offering hope to millions of people living with anxiety.

Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.

Oncology’s Most Eligible Unpartnered Assets

Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.

Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.

Oncology’s Most Eligible Unpartnered Assets

Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.

China’s Biotech Stocks Proved More Resilient Than US’s Amid Market Turmoil

Start-ups from China dominated the fastest-growing share prices for mid-cap biopharma companies in Q1, while the biggest decliners were mainly US firms.

First Quarter M&A Activity Rose On The Strength Of Three Deals

The biopharma sector made acquisitions with total potential value of $33.6bn during Q1, up substantially from the $9.5bn of Q4 2024, according to data from Evaluate.